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ABSTRACT
Introduction asthma attacks are responsible for 
considerable morbidity and may be fatal. We aimed to 
identify and weight risk factors for asthma attacks in 
children (5–12 years) in order to inform and prioritise 
care.
Methods We systematically searched six databases 
(May 2016; updated with forward citations January 
2017) with no language/date restrictions. two reviewers 
independently selected studies for inclusion, assessed 
study quality and extracted data. Heterogeneity 
precluded meta-analysis. Weighting was undertaken 
by an expert Panel who independently assessed each 
variable for degree of risk and confidence in the 
assessment (based on study quality and size, effect sizes, 
biological plausibility and consistency of results) and 
then achieved consensus by discussion. assessments 
were finally presented, discussed and agreed at a 
multidisciplinary workshop.
Results From 16 109 records, we included 68 papers 
(28 cohort; 4 case-control; 36 cross-sectional studies). 
Previous asthma attacks were associated with greatly 
increased risk of attack (Ors between 2.0 and 4.1). 
Persistent symptoms (Ors between 1.4 and 7.8) and 
poor access to care (Ors between 1.2 and 2.3) were 
associated with moderately/greatly increased risk. 
a moderately increased risk was associated with 
suboptimal drug regimen, comorbid atopic/allergic 
disease, african-american ethnicity (USa), poverty and 
vitamin D deficiency. environmental tobacco smoke 
exposure, younger age, obesity and low parental 
education were associated with slightly increased risk.
Discussion assessment of the clinical and demographic 
features identified in this review may help clinicians 
to focus risk reduction management on the high-risk 
child. Population level factors may be used by health 
service planners and policymakers to target healthcare 
initiatives.
Trial registration number crD42016037464.
InTRoDuCTIon
Asthma is the most common long-term condition 
in children, with European prevalence rates among 
6–7 year-olds ranging from 5% in Albania to 21% 
in the UK.1 Asthma is responsible for substantial 
morbidity, resulting in 2.8 million school days lost 
annually in the UK,2 many involving time off work 
for parents/carers.3 In the UK, more than 25 000 
children are admitted annually with an asthma 
attack.4 Frequent attacks affect the quality of life 
of children and their parents, are associated with 
accelerated loss of lung function5 and may be fatal.
Asthma guidelines recommend that monitoring 
should include regular assessment both of current 
symptom control and future risk of an attack.6 7 
Objective assessment of symptoms may be achieved 
with questionnaires validated in children (eg, Paedi-
atric Asthma Control Questionnaire8; Childhood 
Asthma Control Test9) or morbidity scores (eg, 
Royal College of Physicians three questions10) but 
no evidence-based tools exist for informing assess-
ment of future risk in children.
Guidelines list factors associated with an 
increased risk of attacks,6 including a recent 
history of severe attacks, poor symptom control, 
allergic sensitisation, comorbid rhinitis, exposure 
to environmental tobacco smoke (ETS), high use of 
reliever medication, poor adherence to controller 
medication, obesity, eosinophilia, elevated FENO, 
psychosocial problems and impaired spirom-
etry. The relative contribution of these factors to 
increased risk, and how they may be used to stratify 
Key messages
What is the key question?
 ► What are the factors that could enable 
clinicians and healthcare services to ‘spot 
the child’ (5–12 years) with asthma who is 
at increased risk of a severe asthma attack 
(requiring systemic steroids or hospital care)?
What is the bottom line?
 ► The ‘at-risk’ picture that emerges is of a 
child with persistent symptoms who has 
had previous attacks and is on a suboptimal 
treatment regimen, especially if they have 
poor access to healthcare services or other 
risk factors including comorbid atopic/allergic 
diseases, vitamin D deficiency, living in poverty 
and being of African-American ethnicity.
Why read on?
 ► This systematic review identifies risk factors 
and, based on the consensus view of an Expert 
Panel, weights the factors to enable parents, 
clinicians and healthcare services to target 
evidence-based management on children with 
asthma at most risk of having a severe attack.
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risk is not clear; clarifying this issue has been identified as a 
research priority.7
We were commissioned by Asthma UK to undertake a system-
atic review to identify factors associated with the risk of attacks 
in children aged 5–12 years with asthma and, based on the 
consensus view of a multidisciplinary Expert Panel, to weight 
their importance and the strength of the underpinning evidence 
to inform risk stratification.
MeThoDS
The systematic review is registered with PROSPERO 
(CRD42016037464); the protocol is published.11 We followed 
Cochrane methodology12 and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) reporting 
standards.13
Search strategy
We searched MEDLINE, EMBASE, CINAHL, AMED, 
PsycINFO and CENTRAL in May 2016: with no language or 
date restrictions, identified unpublished and in-progress studies 
from  ClinicalTrials. gov and the ISRCTN registry (https://www. 
isrctn. com), undertook forward and backward citation checks. 
The search strategy was structured to include terms for ‘Asthma’ 
and ‘Exacerbations/Attacks’ and ‘Risk factors/Predictors’.11 
(Online supplementary table S1 gives detailed search strategies.) 
We contacted experts in the field for potentially relevant papers 
and anticipated risk factors to ensure we captured all likely 
predictors.
Selection of studies
After initial deduplication and sift of obviously irrelevant titles 
(NT, SM, SMcL, AudB), two reviewers (NT, SM or AudB and 
SMcL or HP) independently screened titles/abstracts of papers 
identified. Two reviewers (AudB and SMcL) screened the full 
text of potentially eligible studies against review criteria. At 
each stage, disagreements were resolved by team discussion with 
advice from the study Steering Group (the grant holders and 
other members of the ARC group).
Inclusion and exclusion criteria
The focus of the review was to identify factors that increased 
a child’s propensity to asthma attacks. Definitions6 7 14 and key 
decisions regarding operationalising the inclusion/exclusion 
criteria are detailed in table 1. We used the American Thoracic 
Society/European Respiratory Society Task Force14 definition of 
severe asthma attacks: asthma symptoms and/or airway obstruc-
tion outside the normal variation for the patient necessitating a 
short course of oral corticosteroids and/or hospitalisation/emer-
gency department use. The population included were children 
aged 5–12 years with a doctor diagnosis of asthma. Studies with 
a wider range of ages (eg, 3–18 years) were included if children 
aged 5–12 were reported separately or if more than 50% of the 
children were within this age range.
Quality assessment
We assessed study quality using Newcastle-Ottawa Scale for 
cohort, case-control and cross-sectional study designs.15
Table 1 Criteria for the search strategy and rules devised to operationalise inclusion/exclusion criteria
Search strategy Definition Rules to operationalise
Population
‘Asthma’
Children aged 5–12 years with doctor-diagnosed asthma, across all 
severities and degrees of control
We included studies with a wider range of ages if results for children aged 
5–12 years were reported separately or if more than 50% of the children 
were within this age range.
We excluded:
 ► Studies in which the diagnosis of asthma was not doctor diagnosed (eg, 
parent reported).
 ► Epidemiological studies in which the denominator was the general 
population (eg, asthma admissions from deprived/rural/urban 
communities) as opposed to a population of children with asthma.
Any setting
Outcome
‘Exacerbations/Attacks’
Severe asthma attacks as defined by the ATS/ERS Task Force14: asthma 
symptoms and/or objective evidence of obstruction outside the normal 
variation for the patient necessitating (A) a short course (at least 
3 days) of oral corticosteroids, and/or (B) a hospitalisation or emergency 
department visit requiring systemic corticosteroids
We excluded studies assessing risk factors for:
 ► Attacks defined only by use of rescue bronchodilator medication.
 ► Poor control/severe asthma (eg, as defined in GINA6) unless ‘attacks’ 
were listed as a separate outcome.
 ► Failure to recover, relapse, early readmission from an existing attack.
 ► Fatality/intubation/ICU as specific outcomes (though these may be 
included within the definition of severe asthma).
Risk factors/predictors Any feature of the child, family or social context, clinical history, 
examination finding or test routinely available in clinical practice which 
increased the propensity of the child to have an asthma attack
We excluded:
 ► Tests currently only available in the context of research (eg, novel 
biomarkers, genomics).
 ► Triggers for attacks, for example, respiratory tract infections, exposure to 
airborne allergens, exercise.
Any routine clinical care (eg, attendance (or not) at routine reviews) 
and disease-related behaviours (eg, adherence (or not) to preventer 
medication)
We excluded:
 ► Trials of interventions (eg, inhaled steroids, self-management) proven to 
reduce exacerbations because we anticipated confounding by indication.
 ► Complex/multifaceted interventions (eg, enrolled in a local disease 
management initiative) because the impact is unlikely to be 
generalisable.
Study designs Cohort, case-control studies and cross-sectional studies (but not case 
studies and case series)
We included controlled trials if they included an analysis that provided an 
estimate of risk of an attack (eg, cohort or cross-sectional studies from 
baseline data).
ATS, American Thoracic Society; ERS, European Respiratory Society; GINA, Global Initiative for Asthma; ICU, intensive care unit. 
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Data extraction
We extracted details of study design, setting, population, 
methods, risk factors, definition of asthma and attacks, quality 
assessment, statistical analyses and results relevant to our objec-
tives using a piloted form, modified from the Cochrane Effective 
Practice and Organisation of Care data collection form.16 We 
contacted authors to clarify unclear or missing data.
Quality assessment and data extraction were conducted by 
AudB or SMcL and one of eight reviewers (JFK, MW, HB, VD, 
SS, MP, HKZ or ED) trained to undertake independent duplicate 
quality assessment and data extraction. Disagreements in quality 
assessment were independently verified and arbitrated by the 
principal investigator (HP) who also checked the data presented 
in the tables.
The results for each risk factor were entered onto a table 
(online supplementary table S2), in order to facilitate weighting. 
Within each factor, the results were listed from strongest to 
weakest study design (ie, cohort, case-control, then cross-sec-
tional) and then ranked by study quality (quality assessment 
score).
Data synthesis: risk factor weighting
We anticipated that clinical and statistical heterogeneity of data 
would preclude formal meta-analyses. We therefore convened an 
Expert Panel (selected to provide a range of perspectives from 
among senior clinical academics of the Asthma UK Centre for 
Applied Research and the research team) comprising a general 
practitioner (GP) (HP), three respiratory paediatricians (JYP, 
JH, MS) and two researchers with a public health background 
(AudB, JFK), to make weighting decisions by reviewing the ORs 
and CIs, or other relevant statistics, as presented for each risk 
factor in online supplementary table S2. The Panel also had 
access to the full-text papers. The experts initially worked inde-
pendently, and then met to reach consensus on weighting. In 
methodology analogous to the grading of recommendations in 
which both outcomes and quality of evidence are assessed, there 
were two decisions to be made:
1. What is the risk associated with each factor? Following dis-
cussion, thresholds for the risk weighting based on the ma-
jority of ORs for each factor were agreed (see table 2). The 
risk factor weighting ranged from ‘no’, ‘slightly’, ‘moderate-
ly’ or ‘greatly’ increased risk of future attack.
2. How confident is this estimate of risk? The Expert Panel 
based the confidence assessment on the following criteria: 
the number of studies, study design (cohort, case-control 
and cross-sectional), quality of studies included (Newcastle-
Ottawa Scale), consistency of the results and the biological 
plausibility of the factors’ effect on risk of future attacks to 
determine the confidence with which the estimates were 
made. Assessments were rated as ‘highly’, ‘moderately’, 
‘slightly’ confident or ‘inconclusive/insufficient evidence’.
At the consensus meeting, each factor was considered in turn 
and all available data taken into account when reaching the 
decision on risk and confidence. Any subsequent discussion was 
carried out by email.
Data synthesis: overarching risk
Risk factors for which there was sufficient evidence to reach a 
consensus decision on weighting and confidence in the assess-
ment based on the decisions reached during Expert Panel discus-
sion were illustrated on a bubble plot. The position of the bubble 
denotes the weighting of the risk factor and the size of the bubble 
indicates confidence in the estimate.
end-of-project workshop
An end-of-project videoconference (to allow UK-wide partic-
ipation) workshop was held in January 2017, in which the 
researchers and the members of the Expert Panel were joined 
by a multidisciplinary group (n=18: including medical/nursing 
professionals from primary and secondary care, health service 
researchers, patient and public involvement (PPI) members) 
who reviewed and helped interpret the findings. In addition 
to the weighting table, data on each factor were presented to 
the workshop as Forest plots (online supplementary table S3) 
and the bubble plot constructed to visually display the overall 
results. Each risk factor was discussed, the weighting assessment 
reviewed and agreed, and the implications considered from the 
perspective of the different stakeholders.
Patient and public involvement
Two parents of children with asthma (recruited from the Asthma 
UK Centre for Applied Research PPI Group) were involved 
throughout the study. In addition, representatives of Asthma UK 
attended the end-of-project workshop.
updating prior to publication
In order to update the review prior to publication, we under-
took forward citation on all included studies (January 2017). 
Pursuing references from included studies is an efficient 
approach to updating systematic reviews as it is unlikely that 
relevant papers will have been published without citing at least 
one of the included studies.17
ReSulTS
Search results
The searches yielded 21 963 records. Figure 1 (PRISMA diagram) 
gives details of the search and selection process. After deduplica-
tion and title/abstracts screening, 209 papers remained for full-
text review of which 45 were included. Forward and backward 
citations yielded 23 additional papers; thus, 68 studies were 
included in the final analysis.
Characteristics of studies
Of the 68 studies, 28 were cohort,18–47 4 were case-control48–51 
and 36 were cross-sectional studies.52–85 Study size varied mark-
edly from 38 participants with severe asthma in a study from the 
Netherlands20 to 6.7 million participants in a US census-based 
study.77 The studies came from 10 countries: 53 were based in 
the USA,18 19 21–24 27 28 30–46 49 51–54 57–61 63 65 66 68 70 71 73 74 76–78 80–84 86 
5 in the Netherlands,20 29 47 48 64 3 in Puerto Rico,50 55 56 2 in 
Table 2 Thresholds for weighting risk factors
Description
Thresholds and criteria for 
decision
Risk weighting (OR) Greatly increased risk Majority of ORs >2.5
Moderately increased risk Majority of ORs 1.5–2.5
Slightly increased risk Majority of ORs 1.1–1.5
No effect Majority of ORs <1.1
Confidence Highly confident Number, design and quality of 
studies, consistency of results, 
biological plausibility of factors
Moderately confident
Slightly confident
Inconclusive Unable to decide on risk Inconsistent or insufficient 
evidence
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Canada,26 62 and 1 each in Brazil,75 Chile,72 Costa Rica,69 France,67 
Trinidad79 and the UK.25 Publication dates ranged from 199374 
to 2017.18
The studies were heterogeneous on most characteristics, 
including population size, recruitment strategy, definitions of 
risk factors and attacks, and analytical approaches (confirming 
our decision that meta-analysis was not appropriate). Figure 2 
shows how key variables are illustrated in the Forest plots.
Study quality varied (figures 3–6; online supplementary table 
S2). Most studies adjusted for at least age and gender, though 10 
studies did not report adjusting for any potential confounders, 
reducing their quality score.28 45 47 62 67 79 81 83–85
overview of results
There were 33 risk factors identified, covering asthma disease 
status, medication use, allergy/atopy, social context, care and 
services, environment, and demography. Online supplementary 
table S2 is the full weighting table containing detailed informa-
tion about populations studied, definitions used and analyses 
performed grouped by risk factor. Online supplementary table S3 
summarises the data for each risk factor (including Forest plots 
of ORs where there were sufficient data) and the rationale for 
the weighting decisions. Figures 3–6 summarise the two detailed 
supplementary tables including simplified Forest plots. The text 
below synthesises the findings and weighting for each risk factor.
The overarching risk assessment is illustrated in a bubble plot 
(figure 7).
Greatly or moderately/greatly increased risk of attacks (figure 
3)
Previous attacks (n=11)
Previous attacks were consistently associated with a greatly 
increased risk of future attacks (ORs between 2.0 and 
4.1).25 27 29 35–37 43 44 69 81 84 Due to the consistency of findings 
and quality of the studies the Panel was highly confident in this 
assessment (figure 3).
Poor control and/or persistent symptoms (n=11)
Ten studies had at least one significant result demonstrating 
that poor control or persistent symptoms identified a child at 
moderately/greatly increased risk of future attacks (ORs between 
1.4 and 7.8).20 27 38 41 49 62 65 69 75 85 The exception was a small 
(n=165), short duration (3 months) cohort study of moderate 
quality which showed no association.45 The Panel was highly 
confident in this assessment. Persistent symptoms of any severity 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. ATS, American Thoracic Society; ERS, 
European Respiratory Society. 
Figure 2 Key variables and key to Forest plots. ED, emergency department. 
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(as opposed to intermittent symptoms) were associated with 
greater risk.27 38 45 65 69
Poor access to healthcare (n=5)
Five studies examined access to healthcare defined by insur-
ance status. Four demonstrated that poor access to healthcare 
was associated with a moderately/greatly increased risk of 
attacks.61 65 82 85 A small cohort study of moderate quality demon-
strated no increased risk in children with or without Medicaid 
(a US social welfare programme).45 The Panel was moderately 
confident in this assessment. The studies were all US based with 
participants from deprived inner-city populations: one study 
controlled for ethnicity and poverty.65
Moderately increased risk of attacks
Suboptimal drug regimen (n=9)
Five of the seven studies that examined high reliever (short-acting 
beta2 agonist (SABA)) use showed a positive association with risk of 
attacks.25 36 43 49 54 The increased risk was judged to be slight (ORs 
between 1.2 and 1.3 in the three larger studies25 36 49), though none 
of the studies assessed very high levels of SABA use (figure 4).
Paradoxically, controller medication use was associated 
with an increased risk of attacks, as clinicians followed guide-
line recommendations and prescribed inhaled corticosteroids 
to children with poor control and previous exacerbations 
(‘confounding by indication’). Sixteen studies were included in 
this category: nine were suggestive of confounding by indica-
tion,25 29 48 50 53 55 56 59 81 four demonstrated fewer exacerbations 
with controller use18 35 36 84 and three showed no effect.31 65 69
The most sensitive marker of moderately increased risk was 
the ratio of controller-to-total medication. Suboptimal regimens 
were typically defined (in accordance with Healthcare Effective-
ness Data and Information Set criteria86) as a ratio of the number 
of prescriptions for controller medication to total number of 
prescriptions for asthma medication <0.5. Six of seven studies 
that used this marker showed a significant relationship between 
a suboptimal regimen and asthma attacks (ORs between 1.2 and 
2.318 24 26 31 53 54). In other approaches, two large, high-quality 
cohort studies showed an association with use of regular medi-
cation and fewer attacks.23 29 Thus, the Panel considered that a 
suboptimal regimen was associated with moderately increased 
risk, and were highly confident in their assessment.
Comorbid atopic/allergic diseases (n=6)
Two large, high-quality cohort studies analysed primary care 
records from the UK25 and the Netherlands.29 The UK study 
found comorbid allergic rhinitis increased the odds of hospi-
talisation by 2.3 (95% CI 1.4 to 3.9),25 whereas the Nether-
lands study found no increased risk of attacks in children with 
comorbid eczema (RR 0.8, 95% CI 0.4 to 1.4), allergic rhinitis 
(RR 0.8, 95% CI 0.5 to 1.2) or conjunctivitis (RR 1.4, 95% CI 
0.7 to 2.7) compared with no comorbid allergic disease.29
Figure 3 Greatly increased risk: evidence for risk factors and weighting decisions. Note: The scale on all the Forest plots has been curtailed at an 
OR of 8 to enable comparison between the plots for the different factors. If the CIs are very wide, and the upper limit extends beyond the plot this is 
indicated with a line with an arrow. (95% CIs are given in online supplementary table S2 if required.) ED, emergency department.
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The remaining four cross-sectional studies all demonstrated at 
least one positive association between comorbid atopic/allergic 
conditions and risk of attacks though CIs were wide.64 70 75 79 The 
Panel concluded that that there was a moderately increased risk of 
attacks with comorbid atopic/allergic disease, but they were only 
slightly confident in this assessment.
African-American ethnicity (n=12)
Twelve US-based studies examined the association 
between African-American ethnicity/‘race’ and the risk of 
attacks.18 22 38 45 52 53 56 61 65 78 81 82 Of the 12 studies, 10 reported 
at least one significant result demonstrating an increased risk of 
attacks in African-Americans compared with white or ‘non-black’ 
children (ORs between 1.6 and 4.1).18 22 38 52 53 61 65 78 81 82 The 
exceptions were a study that assessed the impact of African ancestry 
in a Puerto Rican population,56 and a small cohort study.45
Six of these studies demonstrated that the increased risk in Afri-
can-Americans persisted after controlling for deprivation and/or 
poverty,60 65 area of residence,61 healthcare provision22 38 53 61 65 
or parental education.52 Two studies compared risk in Black and 
Hispanic populations22 52: the risk was considerably less in Hispanic 
populations. Overall, the Panel was highly confident that Afri-
can-American ethnicity was associated with moderately increased 
risk of asthma attacks.
Vitamin D deficiency (n=4)
Three small studies showed a significant association between 
vitamin D insufficiency (vitamin D <30 ng/mL) and acute attacks 
(ORs between 2.2 and 2.8),50 56 83 though a larger (n=1024) cohort 
study found only a borderline effect (OR 1.4, 95% CI 1.0 to 1.9).32 
Thus, the Panel was slightly confident that vitamin D deficiency 
was associated with a moderately increased risk of attacks.
Figure 4 Moderately increased risk: evidence for risk factors and weighting decisions. Note: The scale on all the Forest plots has been curtailed at 
an OR of 8 to enable comparison between the plots for the different factors. If the CIs are very wide, and the upper limit extends beyond the plot 
this is indicated with a line with an arrow. (95% CIs are given in online supplementary table S2 if required.) ED, emergency department; ICS, inhaled 
corticosteroid; LABA, long-acting β2 agonist. 
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Poverty (n=9)
Nine studies examined the effects of poverty (variously defined 
as annual family income <US$15 000; <US$20 000; <US$40 
000; receiving benefits) on risk of attacks in children with 
asthma. Seven studies had at least one positive association 
between risk of attacks and poverty level (ORs between 1.4 and 
2.8).30 49 55 62 65 82 85 The exceptions were two small Puerto Rican 
studies.50 56 The Panel was moderately confident that poverty 
moderately increased risk of attacks.
Slightly increased risk of attacks
ETS exposure (n=8)
Five studies found at least one positive association between 
ETS exposure and asthma attacks.42 60 62 74 85 One high-quality 
cross-sectional study highlighted that the association between 
cotinine levels and risk of attack was lost when parent report 
was used to estimate ETS.60 Of note, the three negative studies 
relied on parental report.51 55 82 The Panel was highly confident 
that ETS exposure was associated with a slightly increased risk 
of asthma attack (figure 5).
Younger age (n=6)
All six of the studies that examined the effect of age on risk of 
asthma attacks found that younger children (within the 5–12 age 
range) were more likely to have an attack.18 36 39 61 81 82 The ORs 
ranged from 0.8 to 1.0 (indicating slightly decreased risk as age 
increased); the Panel was highly confident of this.
Overweight/obesity (n=10)
Four studies (including three very large high-quality studies) 
showed a significant, though small association between over-
weight or obesity and increased risk of attacks.21 30 52 80 The 
Panel was highly confident that there was a slightly increased 
risk of an attack in overweight or obese children.
Low parental education (n=4)
All four studies,49 52 55 62 including one large, high-quality 
cross-sectional study,52 showed slightly increased risk of attacks 
in children of families with low parental education level (ORs 
between 1.1 and 1.9). The Panel was moderately confident in 
this assessment.
no effect on risk of attacks
Gender (n=14)
Two studies found girls at an increased risk of attacks,52 53 and 
three found boys at increased risk18 60 65; the other nine studies 
showed no gender difference.29 36 38 45 61 62 77 81 85 Thus, the Panel 
Figure 5 Slightly increased risk: evidence for risk factors and weighting decisions. Note: The scale on all the Forest plots has been curtailed at an 
OR of 8 to enable comparison between the plots for the different factors. If the CIs are very wide, and the upper limit extends beyond the plot this is 
indicated with a line with an arrow. (95% CIs are given in online supplementary table S2 if required.) SABA, short-acting beta2 agonist. 
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was highly confident that the child’s gender had no effect on risk 
of attacks (figure 6).
Hispanic population (n=9)
Overall, the findings in the US Hispanic population were incon-
sistent; with the majority of studies demonstrating no increased 
risk,38 60 63 or inconsistent risk across the outcome measures 
used.52 Four studies showed a small increased risk18 22 82 (one 
with very wide CIs65) and one showed a reduced risk of emer-
gency department visits.53 The Panel thus concluded that overall 
there was no increased risk, but their confidence in this assess-
ment was only moderate.
Urban residence/proximity to major roads (n=6)
One case-control study showed a small increased risk of attacks 
in children living very close to a major road.50 The other five 
studies45 53 57 61 73 were negative including two large, high-quality 
cross-sectional studies, which controlled for a broad range of 
confounders.53 57 The Panel was slightly confident in their assess-
ment of no effect.
Confounded by severity
Controller medication use, nebuliser use, ownership of written 
asthma action plans and routine asthma reviews were all 
associated with increased risk of attacks and were considered by 
the panel to be confounded by severity. (For details see online 
supplementary tables S2 and S3).
Insufficient evidence to draw a conclusion
For 12 factors we found inconclusive/insufficient evidence to 
draw a conclusion. These are listed at the end of figure 6; details 
about why the data were considered to be inconclusive/insuffi-
cient are provided in online supplementary table S3, with full 
description of all the studies in online supplementary table S2.
DISCuSSIon
Main findings
This systematic review aimed to identify factors which would 
identify children aged 5–12 years with asthma who are at 
increased risk of acute attacks. The child who had a history 
of previous attacks and persistent asthma symptoms was at 
greatly increased risk of a future attack, especially if they had 
poor access to care. Other key markers of moderately increased 
risk were a suboptimal drug regimen, comorbid atopic/allergic 
disease, African-American ethnicity, poverty and vitamin D defi-
ciency. Younger age, exposure to ETS, being overweight and low 
parental education were associated with a slightly increased risk, 
Figure 6 No increased risk, confounded and inconclusive factors: evidence for weighting decision. Note: The scale on all the Forest plots has been 
curtailed at an OR of 8 to enable comparison between the plots for the different factors. If the CIs are very wide, and the upper limit extends beyond 
the plot this is indicated with a line with an arrow. (95% CIs are given in online supplementary table S2 if required).
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but gender, urban residence and Hispanic ethnicity were not 
associated with increased risk.
Strengths and limitations
Despite our wide-ranging search strategies, we may not have 
identified all significant risk factors. Nevertheless, we identi-
fied papers related to almost all the predictors suggested by 
guidelines and experts in the field, lending face validity to our 
findings. The main omissions were that preterm delivery and 
eosinophilia were suggested, but not investigated as risk factors 
in any of the studies that we identified. That an additional 23 
studies were found during forward and backward citations 
demonstrates the challenge in developing a comprehensive, 
but manageable, search strategy in such a broad area. There 
were some factors about which we found very little evidence 
and were thus unable to reach a conclusion (eg, comorbidities, 
parental health, FENO testing); lack of evidence, however, does 
not mean they are not significant factors. We excluded factors 
not available in routine clinical practice (eg, novel biomarkers87) 
which means that our conclusions are immediately transferable 
to contemporary clinical practice. The overweight of data from 
the USA (78% of studies included) limits the generalisability 
of the evidence for some factors (eg, ethnicity, poverty, access 
to healthcare) which may not be directly transferrable to other 
healthcare contexts.
The heterogeneity of the studies in terms of definitions of 
attacks (hospitalisations, emergency department visits, unsched-
uled GP care, oral steroids courses), thresholds applied to 
predictors (eg, definitions of persistent/severe symptoms, income 
levels associated with poverty, objective or reported assessment 
of ETS), duration of follow-up, provenance of data (collected 
for research or routine data) as well as study design and anal-
ysis precluded meta-analysis. To reduce potential subjectivity, 
we adopted a rigorous approach to weighting the factors using 
an Expert Panel’s consensus to define initial weightings and a 
multidisciplinary end-of-project workshop at which the findings 
were discussed, refined and agreed. This breadth of internation-
ally recognised professional experience (although all UK based) 
assisted the interpretation of our findings and lends credibility 
to our conclusions.
Figure 7 Summary of risk factors and weighting. ETS, environmental tobacco smoke; ICS, inhaled corticosteroid; SABA, short-acting beta2agonist. 
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Implications for parents and clinical practice
Our findings suggest that it is possible to identify the ‘high-risk’ 
child with asthma. The factors associated with moderately or 
greatly increased risk are easily identifiable in routine practice. 
For example: a history of acute attacks, persistent troublesome 
symptoms, frequency of prescription requests and comorbid 
atopic/allergic conditions are recommended components of 
regular reviews,6 7 88 and knowledge of the social context is a 
core component of family medicine practice.89 90
Identifying that their child is ‘at-risk’ enables parents to take 
decisions about modifying risk, such as reducing exposure to 
ETS, and reconsidering the necessity for controller treatment 
against their concern about harms of regular medication.91 Clini-
cians alerted to the ‘at-risk’ child can target care, specifically 
instituting evidence-based management (regular controllers6 7; 
supported self-management92) to reduce risk.
Implications for healthcare systems and policymakers
Poor access to care and living in poverty were important risk 
factors that should be targeted by policymakers and health 
service planners to reduce risk of acute attacks in children 
living in high-risk populations. At a public health level, strate-
gies for reducing smoking93 and targeting the growing epidemic 
of obesity in children21 will also contribute to reducing risk. In 
the USA, people from African-American communities living in 
deprived communities are at particular risk.
Implications for future research
Formal prognostic modelling is needed to validate the risk 
factors identified in this review,94 and future research should 
assess whether risk assessment based on these factors improves 
outcomes when used prospectively in routine clinical prac-
tice. Nearly three-quarters of the studies in this review were 
performed in a US setting. Research is needed to understand the 
impact of variables such as poverty, urban/rural living, ethnicity 
and different rates of state/private/no medical insurance in other 
contexts.
ConCluSIon
It is possible with the information available in routine clinical 
practice to identify a child who is at increased risk of an acute 
attack. Many of the risk factors are potentially modifiable by 
parents acting to eliminate ETS or adhere to regular controller 
medication, by clinicians offering evidence-based treatment and 
self-management support, by healthcare systems ensuring equi-
table access to care and by policy initiatives addressing social 
deprivation and the public health challenges of smoking and 
obesity.
Acknowledgements We thank Marshall Dozier (academic Support librarian) for 
help with the search strategy, and Dr John Blakey for practical advice in the early 
stages. 
Collaborators the arc group members: Helen Benson; Steve cunningham; 
Victoria Dalgliesh; gwyneth Davies; Melissa goodbourn; Susan grieve; Jonathan 
grigg; Hayley K Zislis; erin McDonnell; Susan Morrow; Meagan Peterson; Daniel 
russell; Jurgen Schwarze; San Selveindran; nara tagiyeva; Mike thomas; Marissa 
Ware; andrew Wilson.
Contributors HP led the development of the protocol, securing of funding, study 
administration, expert panel, workshop and writing of the paper. aS, SJ, aB, JH and 
MS contributed to the development of the protocol. SJ provided statistical advice. 
audB and SMcl undertook the screening, data extraction and presentation of results. 
HP, JYP, JH, MS, audB and JFK formed the expert panel. all authors contributed to the 
interpretation of the findings. audB wrote the initial draft of the paper with SMcl 
and HP, to which all the authors contributed. HP is the study guarantor.
Funding this research was supported by asthma UK (ref: aUK-Sr-2015-01), with 
contributions from the asthma UK centre for applied research (aUK-ac-2012-01). 
aS is supported by the Farr institute which is funded by a consortium of funders 
headed by the Mrc.
Competing interests none declared.
Patient consent not required.
Provenance and peer review not commissioned; externally peer reviewed.
Data sharing statement all data are provided in the manuscript and online 
supplementary tables.
open Access this is an Open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY-nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. all rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
ReFeRenCeS
 1 gibson gJ, loddenkemper r, Sibille Y, et al. The European Lung White Book: 
Respiratory health and disease in Europe. Sheffield, UK: european respiratory Society, 
2013.
 2 Mukherjee M, Stoddart a, gupta rP, et al. the epidemiology, healthcare and societal 
burden and costs of asthma in the UK and its member nations: analyses of standalone 
and linked national databases. BMC Med 2016;14:113.
 3 Bahadori K, Doyle-Waters MM, Marra c, et al. economic burden of asthma: a 
systematic review. BMC Pulm Med 2009;9:24.
 4 royal college of Physicians. Why asthma still kills: the National Review of Asthma 
Deaths (NRAD) Confidential Enquiry report. london: rcP, 2014.
 5 Bai tr, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function 
decline in asthma. Eur Respir J 2007;30:452–6.
 6 global initiative for asthma. global Strategy for asthma Management and Prevention. 
2017. http://www. ginasthma. org (accessed aug 2017).
 7 British thoracic Society/Scottish intercollegiate guideline network. British guideline 
on the Management of asthma. 2016. http://www. sign. ac. uk/ sign- 153- british- 
guideline- on- the- management- of- asthma. html (accessed aug 2017).
 8 Juniper eF, gruffydd-Jones K, Ward S, et al. asthma control Questionnaire in children: 
validation, measurement properties, interpretation. Eur Respir J 2010;36:1410–6.
 9 liu aH, Zeiger r, Sorkness c, et al. Development and cross-sectional validation of the 
childhood asthma control test. J Allergy Clin Immunol 2007;119:817–25.
 10 Pinnock H, Burton c, campbell S, et al. clinical implications of the royal college of 
Physicians three questions in routine asthma care: a real-life validation study. Prim 
Care Respir J 2012;21:288–94.
 11 tagiyeva n, Mclean S, Sheikh a, et al. Protocol for a systematic review to identify and 
weight the indicators of risk of asthma exacerbations in children aged 5-12 years. NPJ 
Prim Care Respir Med 2017;27:16088.
 12 Higgins JPt, green S. cochrane Handbook for Systematic reviews of interventions 
Version 5.1.0. http:// handbook. cochrane. org (accessed aug 2017).
 13 Moher D, liberati a, tetzlaff J, et al. Preferred reporting items for systematic reviews 
and meta-analyses: the PriSMa statement. PLoS Med 2009;6:e1000097.
 14 reddel HK, taylor Dr, Bateman eD, et al. on behalf of the atS/erS task Force on 
asthma control and exacerbations: an Official american thoracic Society/european 
respiratory Society statement: asthma control and exacerbations standardizing 
endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 
2009;180:59–99.
 15 Wells ga, Shea B, O’connell D, et al. the newcastle-Ottawa Scale (nOS) for assessing 
the quality of non-randomised studies in meta-analyses. http://www. ohri. ca/ programs/ 
clinical_ epidemiology/ oxford. asp (accessed aug 2017).
 16 cochrane effective Practice and Organisation of care. ePOc resources for review 
authors. http:// epoc. cochrane. org/ resources/ epoc- resources- review- authors (accessed 
august 2017).
 17 greenhalgh t, Peacock r. effectiveness and efficiency of search methods in systematic 
reviews of complex evidence: audit of primary sources. BMJ 2005;331:1064–5.
 18 Baltrus P, Xu J, immergluck l, et al. individual and county level predictors of asthma 
related emergency department visits among children on Medicaid: a multilevel 
approach. J Asthma 2017;54:53–61.
 19 adams rJ, Fuhlbrigge a, Finkelstein Ja, et al. impact of inhaled antiinflammatory 
therapy on hospitalization and emergency department visits for children with asthma. 
Pediatrics 2001;107:706–11.
 20 robroeks cM, van Vliet D, Jöbsis Q, et al. Prediction of asthma exacerbations in 
children: results of a one-year prospective study. Clin Exp Allergy 2012;42:792–8.
 21 Black MH, Zhou H, takayanagi M, et al. increased asthma risk and asthma-related 
health care complications associated with childhood obesity. Am J Epidemiol 
2013;178:1120–8.
 o
n
 23 July 2018 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2017-210939 on 5 June 2018. Downloaded from 
11Buelo A, et al. Thorax 2018;0:1–12. doi:10.1136/thoraxjnl-2017-210939
Asthma
 22 Stewart Ka, Higgins Pc, Mclaughlin cg, et al. Differences in prevalence, treatment, 
and outcomes of asthma among a diverse population of children with equal access 
to care: findings from a study in the military health system. Arch Pediatr Adolesc Med 
2010;164:720–6.
 23 Spahn J, Sheth K, Yeh WS, et al. Dispensing of fluticasone propionate/salmeterol 
combination in the summer and asthma-related outcomes in the fall. J Allergy Clin 
Immunol 2009;124:1197–203.
 24 andrews al, Simpson an, Basco Wt, et al. asthma medication ratio predicts 
emergency department visits and hospitalizations in children with asthma. Medicare 
Medicaid Res Rev 2013;3:e1–10.
 25 thomas M, Kocevar VS, Zhang Q, et al. asthma-related health care resource use 
among asthmatic children with and without concomitant allergic rhinitis. Pediatrics 
2005;115:129–34.
 26 Zhang t, Smith Ma, camp Pg, et al. High use of health services in patients with 
suboptimal asthma drug regimens: a population-based assessment in British 
columbia, canada. Pharmacoepidemiol Drug Saf 2013;22:744–51.
 27 Haselkorn t, Zeiger rS, chipps Be, et al. recent asthma exacerbations predict future 
exacerbations in children with severe or difficult-to-treat asthma. J Allergy Clin 
Immunol 2009;124:921–7.
 28 Peters Ji, McKinney JM, Smith B, et al. impact of obesity in asthma: evidence from 
a large prospective disease management study. Ann Allergy Asthma Immunol 
2011;106:30–5.
 29 engelkes M, Janssens HM, de ridder Ma, et al. real life data on incidence and 
risk factors of severe asthma exacerbations in children in primary care. Respir Med 
2016;119:48–54.
 30 Schatz M, Zeiger rS, Zhang F, et al. Overweight/obesity and risk of seasonal asthma 
exacerbations. J Allergy Clin Immunol Pract 2013;1:618–22.
 31 Farber HJ, chi FW, capra a, et al. Use of asthma medication dispensing patterns 
to predict risk of adverse health outcomes: a study of Medicaid-insured children in 
managed care programs. Ann Allergy Asthma Immunol 2004;92:319–28.
 32 Brehm JM, Schuemann B, Fuhlbrigge al, et al. Serum vitamin D levels and severe 
asthma exacerbations in the childhood asthma Management Program study. J Allergy 
Clin Immunol 2010;126:52–8.
 33 Pongracic Ja, Visness cM, gruchalla rS, et al. effect of mouse allergen and rodent 
environmental intervention on asthma in inner-city children. Ann Allergy Asthma 
Immunol 2008;101:35–41.
 34 Pongracic Ja, O’connor gt, Muilenberg Ml, et al. Differential effects of outdoor 
versus indoor fungal spores on asthma morbidity in inner-city children. J Allergy Clin 
Immunol 2010;125:593–9.
 35 tolomeo c, Savrin c, Heinzer M, et al. Predictors of asthma-related pediatric 
emergency department visits and hospitalizations. J Asthma 2009;46:829–34.
 36 Schatz M, cook eF, Joshua a, et al. risk factors for asthma hospitalizations in a 
managed care organization: development of a clinical prediction rule. Am J Manag 
Care 2003;9:538–47.
 37 Wu ac, tantisira K, li l, et al. Predictors of symptoms are different from predictors of 
severe exacerbations from asthma in children. Chest 2011;140:100–7.
 38 Kwong KY, Morphew t, Scott l, et al. asthma control and future asthma-
related morbidity in inner-city asthmatic children. Ann Allergy Asthma Immunol 
2008;101:144–52.
 39 Murray MD, Stang P, tierney WM. Health care use by inner-city patients with asthma. J 
Clin Epidemiol 1997;50:167–74.
 40 Mccormack Mc, aloe c, curtin-Brosnan J, et al. guideline-recommended fractional 
exhaled nitric oxide is a poor predictor of health-care use among inner-city children 
and adolescents receiving usual asthma care. Chest 2013;144:923–9.
 41 Haselkorn t, Fish Je, Zeiger rS, et al. consistently very poorly controlled asthma, as 
defined by the impairment domain of the expert Panel report 3 guidelines, increases 
risk for future severe asthma exacerbations in the epidemiology and natural History 
of asthma: Outcomes and treatment regimens (tenOr) study. J Allergy Clin Immunol 
2009;124:895–902.
 42 rabinovitch n, reisdorph n, Silveira l, et al. Urinary leukotriene e4 levels identify 
children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin 
Immunol 2011;128:323–7.
 43 Zeiger rS, Yegin a, Simons Fe, et al. evaluation of the national Heart, lung, and Blood 
institute guidelines impairment domain for classifying asthma control and predicting 
asthma exacerbations. Ann Allergy Asthma Immunol 2012;108:81–7.
 44 covar ra, Szefler SJ, Zeiger rS, et al. Factors associated with asthma exacerbations 
during a long-term clinical trial of controller medications in children. J Allergy Clin 
Immunol 2008;122:741–7.
 45 Halterman JS, Yoos Hl, Sidora K, et al. Medication use and health care contacts 
among symptomatic children with asthma. Ambul Pediatr 2001;1:275–9.
 46 torjusen en, Diette gB, Breysse Pn, et al. Dose-response relationships between mouse 
allergen exposure and asthma morbidity among urban children and adolescents. 
Indoor Air 2013;23:268–74.
 47 Visser ca, Brand Pl. Does a single measurement of exhaled nitric oxide predict 
asthma exacerbations? Arch Dis Child 2011;96:781–2.
 48 Vasbinder ec, Belitser SV, Souverein Pc, et al. non-adherence to inhaled 
corticosteroids and the risk of asthma exacerbations in children. Patient Prefer 
Adherence 2016;10:531–8.
 49 lieu ta, Quesenberry cP, capra aM, et al. Outpatient management practices 
associated with reduced risk of pediatric asthma hospitalization and emergency 
department visits. Pediatrics 1997;100:334–41.
 50 Blatter J, Brehm JM, Sordillo J, et al. Folate deficiency, atopy, and severe asthma 
exacerbations in Puerto rican children. Ann Am Thorac Soc 2016;13:223–32.
 51 Pyle rc, Divekar r, May SM, et al. asthma-associated comorbidities in children 
with and without secondhand smoke exposure. Ann Allergy Asthma Immunol 
2015;115:205–10.
 52 Quinto KB, Zuraw Bl, Poon KY, et al. the association of obesity and asthma severity 
and control in children. J Allergy Clin Immunol 2011;128:964–9.
 53 rust g, Zhang S, reynolds J. inhaled corticosteroid adherence and emergency 
department utilization among Medicaid-enrolled children with asthma. J Asthma 
2013;50:769–75.
 54 Vernacchio l, trudell eK, Muto JM. correlation of care process measures with 
childhood asthma exacerbations. Pediatrics 2013;131:e136–43.
 55 rosas-Salazar c, ramratnam SK, Brehm JM, et al. Parental numeracy and asthma 
exacerbations in Puerto rican children. Chest 2013;144:92–8.
 56 Brehm JM, acosta-Pérez e, Klei l, et al. Vitamin D insufficiency and severe asthma 
exacerbations in Puerto rican children. Am J Respir Crit Care Med 2012;186:140–6.
 57 Pesek rD, Vargas Pa, Halterman JS, et al. a comparison of asthma prevalence and 
morbidity between rural and urban schoolchildren in arkansas. Ann Allergy Asthma 
Immunol 2010;104:125–31.
 58 lang Je, Hossain J, Smith K, et al. asthma severity, exacerbation risk, and controller 
treatment burden in underweight and obese children. J Asthma 2012;49:456–63.
 59 Bacharier lB, Dawson c, Bloomberg gr, et al. Hospitalization for asthma: atopic, 
pulmonary function, and psychological correlates among participants in the childhood 
asthma Management Program. Pediatrics 2003;112:e85–92.
 60 Mccarville M, Sohn MW, Oh e, et al. environmental tobacco smoke and asthma 
exacerbations and severity: the difference between measured and reported exposure. 
Arch Dis Child 2013;98:510–4.
 61 Sarpong SB, Karrison t. Sensitization to indoor allergens and the risk for asthma 
hospitalization in children. Ann Allergy Asthma Immunol 1997;79:455–9.
 62 Dales re, choi B, chen Y, et al. influence of family income on hospital visits for 
asthma among canadian school children. Thorax 2002;57:513–7.
 63 Findley S, lawler K, Bindra M, et al. elevated asthma and indoor environmental 
exposures among Puerto rican children of east Harlem. J Asthma 2003;40:557–69.
 64 arabkhazaeli a, Vijverberg SJ, van erp Fc, et al. characteristics and severity of asthma 
in children with and without atopic conditions: a cross-sectional study. BMC Pediatr 
2015;15:172.
 65 Stingone Ja, claudio l. asthma and enrollment in special education among urban 
schoolchildren. Am J Public Health 2006;96:1593–8.
 66 Stingone Ja, claudio l. Disparities in the use of urgent health care services among 
asthmatic children. Ann Allergy Asthma Immunol 2006;97:244–50.
 67 Mahut B, Beydon n, Delclaux c. Overweight is not a comorbidity factor during 
childhood asthma: the growthOb study. Eur Respir J 2012;39:1120–6.
 68 Wiesenthal en, Fagnano M, cook S, et al. asthma and overweight/obese: double 
trouble for urban children. J Asthma 2016;53:485–91.
 69 Forno e, Fuhlbrigge a, Soto-Quirós Me, et al. risk factors and predictive clinical scores 
for asthma exacerbations in childhood. Chest 2010;138:1156–65.
 70 Friedlander Jl, Sheehan WJ, Baxi Sn, et al. Food allergy and increased asthma morbidity in 
a school-based inner-city asthma study. J Allergy Clin Immunol 2013;1:479–84.
 71 Sunshine J, Song l, Krieger J. Written action plan use in inner-city children: is it 
independently associated with improved asthma outcomes? Ann Allergy Asthma 
Immunol 2011;107:207–13.
 72 castro-rodriguez Ja, ramirez aM, toche P, et al. clinical, functional, and epidemiological 
differences between atopic and nonatopic asthmatic children from a tertiary care hospital 
in a developing country. Ann Allergy Asthma Immunol 2007;98:239–44.
 73 Brown MS, Sarnat Se, DeMuth Ka, et al. residential proximity to a major roadway is 
associated with features of asthma control in children. PLoS One 2012;7:e37044.
 74 chilmonczyk Ba, Salmun lM, Megathlin Kn, et al. association between exposure to 
environmental tobacco smoke and exacerbations of asthma in children. N Engl J Med 
1993;328:1665–9.
 75 lasmar lMlBF, camargos PaM, Ordones aB, et al. Prevalence of allergic rhinitis 
and its impact on the use of emergency care services in a group of children and 
adolescents with moderate to severe persistent asthma. J Pediatr 2007;83:555–61.
 76 rabito Fa, carlson J, Holt eW, et al. cockroach exposure independent of sensitization 
status and association with hospitalizations for asthma in inner-city children. Ann 
Allergy Asthma Immunol 2011;106:103–9.
 77 akinbami lJ, Moorman Je, garbe Pl, et al. Status of childhood asthma in the United 
States, 1980-2007. Pediatrics 2009;123(Suppl3):S131–45.
 78 Malhotra K, Baltrus P, Zhang S, et al. geographic and racial variation in asthma 
prevalence and emergency department use among Medicaid-enrolled children in 14 
southern states. J Asthma 2014;51:913–21.
 79 Pinto Pereira lM, Jackman J, Figaro n, et al. Health burden of co-morbid asthma and 
allergic rhinitis in West indian children. Allergol Immunopathol 2010;38:129–34.
 80 Stingone Ja, ramirez OF, Svensson K, et al. Prevalence, demographics, and health 
outcomes of comorbid asthma and overweight in urban children. J Asthma 
2011;48:876–85.
 o
n
 23 July 2018 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2017-210939 on 5 June 2018. Downloaded from 
12 Buelo A, et al. Thorax 2018;0:1–12. doi:10.1136/thoraxjnl-2017-210939
Asthma
 81 Quezada W, Kwak eS, reibman J, et al. Predictors of asthma exacerbation among 
patients with poorly controlled asthma despite inhaled corticosteroid treatment. Ann 
Allergy Asthma Immunol 2016;116:112–7.
 82 Wood Pr, Smith la, romero D, et al. relationships between welfare status, health 
insurance status, and health and medical care among children with asthma. Am J 
Public Health 2002;92:1446–52.
 83 Searing Da, Zhang Y, Murphy Jr, et al. Decreased serum vitamin D levels in children 
with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 
2010;125:995–1000.
 84 Butz aM, eggleston P, Huss K, et al. nebulizer use in inner-city children with asthma: 
morbidity, medication use, and asthma management practices. Arch Pediatr Adolesc 
Med 2000;154:984–90.
 85 canino g, garro a, alvarez MM, et al. Factors associated with disparities in emergency 
department use among latino children with asthma. Ann Allergy Asthma Immunol 
2012;108:266–70.
 86 national committee for Quality assurance. Use of appropriate medications for people 
with asthma and medication management for people with asthma. http://www. ncqa. 
org/ report- cards/ health- plans/ state- of- health- care- quality/ 2016- table- of- contents/ 
asthma (accessed Jun 2017).
 87 Puranik S, Forno e, Bush a, et al. Predicting severe asthma exacerbations in children. 
Am J Respir Crit Care Med 2017;195:854–9.
 88 Pinnock H, Fletcher M, Holmes S, et al. Setting the standard for routine asthma 
consultations: a discussion of the aims, process and outcomes of reviewing people 
with asthma in primary care. Prim Care Respir J 2010;19:75–83.
 89 WOnca europe. The European definition of General Practice and Family Medicine. 
3rd edn, 2011. (accessed Jun 2017).
 90 eaton S, roberts S, turner B. Delivering person centred care in long term conditions. 
BMJ 2015;350:h181.
 91 Horne r, chapman Sc, Parham r, et al. Understanding patients’ adherence-related 
beliefs about medicines prescribed for long-term conditions: a meta-analytic review of 
the necessity-concerns Framework. PLoS One 2013;8:e80633.
 92 Pinnock H, Parke Hl, Panagioti M, et al. Systematic meta-review of supported self-
management for asthma: a healthcare perspective. BMC Med 2017;15:64.
 93 Mackay D, Haw S, ayres Jg, et al. Smoke-free legislation and hospitalizations for 
childhood asthma. N Engl J Med 2010;363:1139–45.
 94 riley rD, Hayden Ja, Steyerberg eW, et al. Prognosis research Strategy (PrOgreSS) 2: 
prognostic factor research. PLoS Med 2013;10:e1001380.
 o
n
 23 July 2018 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2017-210939 on 5 June 2018. Downloaded from 
